Faeth Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Faeth Therapeutics, Inc. (FTH) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.30% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-04
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 3.90%.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 4.20%, a 5.00% increase year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-03-31 was 4.00%, a 66.67% increase year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2022-03-31 was 2.40%, a 2300.00% increase year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.40%, a 4.35% decline from fiscal 2024.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.60%, a 2.13% decline from fiscal 2023.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.70%, a 11.90% increase from fiscal 2022.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.20%, a 200.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 4.30% 10-Q · filed 2026-08-04 | ||||
| 2026-03-31 | 3.90% 10-Q · filed 2026-05-15 | ||||
| 2025-12-31 | 4.40% 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | 4.40% 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | 4.40% 10-Q · filed 2026-08-04 | ||||
| 2024-12-31 | 4.60% 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | 4.60% 10-Q · filed 2025-11-14 | ||||
| 2024-06-30 | 4.60% 10-Q · filed 2025-08-05 | ||||
| 2024-03-31 | 4.20% 10-Q · filed 2025-05-06 | ||||
| 2023-12-31 | 4.70% 10-K · filed 2025-03-28 | ||||
| 2023-09-30 | 4.60% 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | 4.10% 10-Q · filed 2024-08-06 | ||||
| 2023-03-31 | 4.00% 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | 4.20% 10-K · filed 2024-02-29 | ||||
| 2022-09-30 | 4.00% 10-Q · filed 2023-11-07 | ||||
| 2022-06-30 | 3.20% 10-Q · filed 2023-08-03 | ||||
| 2022-03-31 | 2.40% 10-Q · filed 2023-05-09 | ||||
| 2021-12-31 | 1.40% 10-K · filed 2023-03-29 | ||||
| 2021-09-30 | 1.20% 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | 1.10% 10-Q · filed 2022-08-09 | ||||
| 2021-03-31 | 0.10% 10-Q · filed 2022-05-10 | 1.00% 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | 0.70% 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | 0.18% 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |